Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA Feb. 20, 2024: Theranica, a prescribed digital therapeutics company specialising in neuromodulation devices for migraine and other idiopathic pain conditions, announced the inclusion of its Nerivio Remote Electrical Neuromodulation (REN) wearable, for use in the acute and preventive…
Is Long COVID a brain injury?
Study led by Benedict Michael finds global cognitive deficits A recent study on Preprint server Research Square suggests that brain fog, memory and concentration problems may be due to brain injury caused by the COVID-19 virus. The study found that 351 patients hospitalised with severe COVID-19 had evidence of a long-term brain injury a year…
Potential treatments for secondary brain cancer
Drugs already licensed could be trialled to potentially treat secondary brain cancer, new research finds The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer. Licensed drugs could be clinically trialled to find out if they could treat the disease. The research led by…
Immune response responsible for neurological damage
There has been a long-held belief that acute viral infections are directly responsible for neurological damage, but researchers from McMaster University have now discovered that it is the immune system’s response that is behind it. The research, published on February 5, 2024 in Nature Communications, was led by Elizabeth Balint, a PhD student at McMaster, and…
Biogen drops Alzheimer’s drug Aduhelm
31 January 2024; Biogen has announced that it will discontinue the development and commercialisation of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM programme will…
Emylif – orodispersible film for ALS
January 24, 2024: In November 2023, Zambon UK launched Emylif, a new formulation of riluzole in an orodispersible film – for the treatment of adults with amyotrophic lateral sclerosis (ALS). Emylif offers an alternative to the tablet administration of riluzole which can be difficult for patients to take as their disease progresses and they develop…
Treating spasticity with injection guidance techniques
AboLiSh study demonstrates clinical benefit of injection guidance when treating spasticity with abobotulinumtoxinA 19th January, 2024: Ipsen has announced top line results from its real-world AboLiSh study (NCT04050527), presented at the 7th international TOXINS conference in Berlin, Germany. The study evaluated utilisation and effectiveness of Dysport® (abobotulinumtoxinA) in people living with lower-limb spasticity and found…
CIDP – FDA approval of HYQVIA
FDA approves Takeda’s Immune Globulin Infusion, Hyqvia 16 January, 2024; The U.S. Food and Drug Administration (FDA) has approved HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults. HYQVIA first received approval…
RYSTIGGO®▼ (rozanolixizumab) EC approval
UCB announces European Commission approval of RYSTIGGO®▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe 8th January 2024: UCB, a global biopharmaceutical company, today announced that the European Commission (EC) granted a marketing authorisation for RYSTIGGO® (rozanolixizumab) on 5th January 2024 as an add-on to standard therapy for the treatment of…
